Peter Koulen
One of the most frequently mutated oncogenic pathways in cancer is the MAPK pathway. Although RAS mutations are the most common MAPK changes, changes in downstream components of the pathway, such as the RAF and MEK genes, offer promising therapeutic opportunities. Other alterations in the RAF and MEK genes may provide rarer, but tractable, targets in addition to BRAFV600 mutations, for which several approved therapeutic regimens, exist. Recent studies, however, have demonstrated the complexity of MAPK signalling and highlighted the fact that different alterations in these genes may have strikingly different properties. Understanding the distinct functional properties of specific RAF and MEK alterations, as discussed here, will be critical for developing effective therapeutic approaches for these targets.
இந்தக் கட்டுரையைப் பகிரவும்
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 